Jefferies Healthcare Conference – A fireside chat with Takeda leaders
Takeda President and CEO Christophe Weber, CFO Costa Saroukos, and R&D President Andrew Plump participated a fireside chat at this year’s Jefferies Healthcare Conference. They discussed Takeda’s strong financial results for FY2021, the outlook for FY2022 and what’s driving the company’s growth momentum.
FY2021 was a year of significant topline acceleration for Takeda, with the company recording its fastest underlying revenue growth since we began measuring with this metric in 2013. Our growth strategy is fueled by a balanced and diverse portfolio that includes oncology, rare genetics and hematology, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Within this portfolio, our most important global products and future growth drivers—what we call our Growth and Launch Products—are addressing important unmet needs, bringing substantial value to patients and expanding rapidly to new markets.
In FY2021, Takeda further demonstrated our ability to bring new therapies to patients, receiving our highest total number of approvals in a fiscal year across Japan, China, the U.S., and Europe and leading the industry in drug approvals in Japan in calendar year 2021.
Pipeline development continues to be a priority, and Takeda has one of the most exciting and diverse pipelines in the industry—90 percent of which did not exist six years ago. The company has 10 late-stage development programs for new molecular entities that have upcoming initial filing and expansion opportunities.
We are energized by our prospects for the future! Our purpose to create better health for people and a brighter future for the world is a core foundation of our global growth strategy and will help us create value for decades to come.
View a playback of the fireside chat here.
 Underlying Growth is a Non-IFRS measure, i.e., a measure not calculated and presented in accordance with IFRS. See slides 36, 49 & 51 of Takeda's full-year FY2021 investor presentation (available at takeda.com/investors/financial-results) for further information about Takeda’s Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.
This article and any materials distributed in connection with this article may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this presentation or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this presentation may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.